SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005; 19: 685708.
  • 2
    Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992; 19: 60811.
  • 3
    Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000; 27: 66470.
  • 4
    Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short term mortality in systemic lupus erythematosus with term dependent measures of disease activity. J Rheumatol 2000; 27: 18925.
  • 5
    Danowski A, Magder L, Petri M. Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol 2006; 33: 5760.
  • 6
    Ibanez D, Gladman D, Urowitz M. Summarizing disease features over time. II. Variability measures of SLEDAI-2K. J Rheumatol 2007; 34: 33640.
  • 7
    Swaak AJ, van den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) 1999; 38: 9538.
  • 8
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 44758.
  • 9
    Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996; 55: 75660.
  • 10
    Isenberg DA, Gordon C. From BILAG to BLIPS: disease activity assessment in lupus past, present and future. Lupus 2000; 9: 6514.
  • 11
    Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 936.
  • 12
    Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: a 5-year prospective study. Rheumatology (Oxford) 2004; 43: 103944.
  • 13
    Strand V. Lessons learned from clinical trials in SLE. Autoimmun Rev 2007; 6: 20914.
  • 14
    Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measure to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999; 26: 4907.
  • 15
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 16
    Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1: 92532.
  • 17
    Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nefrology (Carlton) 2005; 10: 50410.
  • 18
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merril JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 114351.
  • 19
    Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988; 69: 92732.
  • 20
    Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 9026.
  • 21
    Yee CS, Isenberg DA, Prabu A, Sokoll K, Rahman A, Bruce IN, et al. BILAG 2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 2008; 67: 8736.
  • 22
    Isenberg DA, Allen E, Farewell V, D'Cruz D, Alarcon GS, Aranow C, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SLEDAI. Ann Rheum Dis 2011; 70: 549.
  • 23
    Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006; 54: 33005.
  • 24
    Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 41139.
  • 25
    Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The BILAG 2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009; 48: 6915.
  • 26
    Yee CS, Cresswell L, Farewell V, Rahman A, Teh LS, Griffiths B, et al. Numerical scoring for the BILAG 2004 index. Rheumatology (Oxford) 2010; 49: 16659.
  • 27
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004; 50: 341826.
  • 28
    Mosca M, Chimenti D, Pratesi F, Baldini C, Anzilotti C, Bombardieri S, et al. Prevalence and clinico-serological correlations of anti-α-Enolasa, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol 2006; 33: 6957.
  • 29
    Amital H, Szekanecz Z, Szucz G, Danko K, Nagy E, Csepany T, et al. Serum concentration of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010; 69: 11557.
  • 30
    Vitali C, Bencivelli W, Isenberg DA, Smoler JS, Snaith ML, Scinto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research II. Identification of the variables indicative of disease activity and their use in the developer of an activity score. Clin Exp Rheumatol 1992; 10: 5417.
  • 31
    Mosca M, Neri R, Giannessi S, Totti D, Bencivelli W, Bombardieri S. The inter-observer variability of the ECLAM index in the evaluation of disease activity in systemic lupus erythematosus [abstract]. Arthritis Rheum 1999; 42 Suppl: S98.
  • 32
    Mosca M, Bencivelli W, Vitali C, Carrai P, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000; 9: 44550.
  • 33
    Fellows of Harvard College. SLE Activity Measure-Revised (SLAM-R). 1988.
  • 34
    Chang ER, Abrahamowics M, Ferland D, Fortin PR. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients' or physicians' evaluations of recent lupus activity. J Rheumatol 2002; 29: 23508.
  • 35
    Zhang J, Gonzales LA, Roseman JM, Vila LM, Reveille JD, Alarcon GS. Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX. Lupus 2010; 19: 72733.
  • 36
    Liang MH, Socher SA, Larsen MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 110718.
  • 37
    Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of Systemic Lupus Activity Measure-Revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001; 10: 4059.
  • 38
    Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994; 21: 146871.
  • 39
    Fortin PR, Abramowicz M, Neville C, du Berger R, Fraenkel L, Clarke AE, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998; 7: 1017.
  • 40
    Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a systemic lupus activity questionnaire (SLAQ) for populations studies. Lupus 2003; 12: 2806.
  • 41
    Trupin L, Tonner MC, Yazdany J, Julian LJ, Criswell LA, Katz PP, et al. The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. J Rheumatol 2008; 35: 17828.
  • 42
    Wolfe F, Petri M, Alarcon GS, Goldman J, Chakravaty EF, Katz RS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 2009; 36: 828.
  • 43
    Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP. Validation of the Systemic Lupus Erythematosus Activity Questionnaire in a large observational cohort. Arthritis Rheum 2008; 59: 13643.
  • 44
    Committee on Prognosis Studies. Prognosis studies in SLE: an activity index [abstract]. Arthritis Rheum 1986; 29 Suppl: S93.
  • 45
    Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 28891.
  • 46
    Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010; 19: 4950.
  • 47
    Uribe AG, Vila LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcon GS. The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004; 31: 193440.
  • 48
    Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 25508.
  • 49
    Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reves P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 253949.
  • 50
    Petri M, Buyon J, Skovron ML, Kim M, for the SELENA Group. Disease activity and health status (SF-36) in postmenopausal systemic lupus erythematosus: the SELENA trial [abstract]. Arthritis Rheum 1997; 40 Suppl: S208.
  • 51
    Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 68591.
  • 52
    Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus: prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 15518.
  • 53
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 54
    Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 24854.
  • 55
    Costenbader KH, Khamashta M, Ruiz-Garcia S, Perez-Rodriguez MT, Petri M, Elliot J, et al. Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res 2010; 62: 55968.
  • 56
    Pons-Estel BA, Sanchez-Guerrero J, Romero-Diaz J, Iglesias-Gamarra A, Bonfa E, Borba EF, et al. Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. Lupus 2009; 18: 103352.
  • 57
    Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 80913.
  • 58
    Gladman DD, Goldsmith C, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for SLE international comparison. J Rheumatol 2000; 27: 3736.